Voriconazole for IPA in Chinese Patients With COPD
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
voriconazole is recommended as first-line therapy for invasive pulmonary aspergillosis,
however the efficacy and safety of voriconazole for treating invasive pulmonary aspergillosis
secondary to COPD is not clear. This study aims to investigate the effectiveness and
tolerability of intravenous voriconazole for treatment of invasive pulmonary aspergillosis in
Chinese patients with COPD, by monitoring changes in clinical symptoms, eradication of
aspergillus, improvement of chest imaging as well as record of possible adverse reactions
following 2-week intravenous instillation of voriconazole.
Phase:
Phase 4
Details
Lead Sponsor:
Red Cross Hospital, Hangzhou, China
Collaborators:
First People's Hospital Affiliated to Huzhou University First People's Hospital of Hangzhou Hangzhou Hospital of Traditional Chinese Medicine Ningbo People's Hospital Second People's Hospital of Hangzhou Sir Run Run Shaw Hospital Xiaoshan Hospital Xiaoshan People's Hospital Zhejiang Provincial People's Hospital Zhejiang Provincial People’s Hospital